| 1 | 10014 | LAO-11030 | ETCTN | Hematopoietic Neoplasm (excluding Leukemia, Lymphoma and Myeloma);Miscellaneous and Metastatic Cancer | Active | A Pilot Study of Atezolizumab (MPDL3280A) Following Adoptive Cell Transfer in Active Hematologic or Solid Tumor Malignancies | Pilot | 20/40 | N/A | INTERVENTION |
| 2 | 10020 | LAO-CT018 | ETCTN | Breast Cancer | Active | A Phase II Open-Label, Randomized Study of PARP Inhibition (Olaparib) Either Alone or in Combination with Anti-PD-L1 Therapy (Atezolizumab; MPDL3280A) in Homologous DNA Repair (HDR) Deficient, Locally Advanced or Metastatic Non-HER2-Positive Breast Cancer | II | 64/90 | N/A | INTERVENTION |
| 3 | 10066 | LAO-CT018 | ETCTN | Gastrointestinal Cancer | Active | A Phase 1/2 Study of Olaparib in Combination with Ramucirumab in Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma (10017760) | I/II | 38/49 | N/A | INTERVENTION |
| 4 | 10150 | LAO-11030 | ETCTN | Female Reproductive System Cancer | Active | A Randomized Phase 2 Study of Bevacizumab and Either Weekly Anetumab Ravtansine or Weekly Paclitaxel in Platinum-Resistant or Platinum Refractory Ovarian Cancer | I/II | 27/96 | N/A | INTERVENTION |
| 5 | 10200 | LAO-MD017 | ETCTN | Leukemia | Active | A Phase Ib/II Study of the Histone Methyltransferase Inhibitor Pinometostat in Combination with Azacitidine in Patients with 11q23-Rearranged Acute Myeloid Leukemia | I/II | 1/48 | N/A | INTERVENTION |
| 6 | 10216 | LAO-OH007 | ETCTN | Lung, Mediastinal, and Pleural Cancer | Active | A Phase I/II Study of AZD9291(Osimertinib) and CB-839 HCl in Patients with EGFR Mutant Non-Small Cell Lung Cancer | I/II | 1/18 | N/A | INTERVENTION |
| 7 | 10302 | LAO-NJ066 | ETCTN | Breast Cancer | Active | Phase II Trial of Radium-223 Dichloride in Combination with Paclitaxel in Patients with Bone Metastatic Breast Cancer | II | 0/70 | N/A | INTERVENTION |
| 8 | 9979 | LAO-MN026 | ETCTN | Miscellaneous and Metastatic Cancer | Active | Phase 1 and Pharmacology Study of Oral 5-Iodo-2-Pyrimidinone-2-Deoxyribose (IPdR) as a Prodrug for IUdR-Mediated Tumor Radiosensitization in Brain Metastases | I | 8/47 | N/A | INTERVENTION |
| 9 | A031102 | ALLIANCE | NCTN | CNS Cancer (Primary tumor);Germ Cell Cancer | Active | A Randomized Phase III Trial Comparing Conventional-Dose Chemotherapy Using Paclitaxel, Ifosfamide, and Cisplatin (TIP) with High-Dose Chemotherapy Using Mobilizing Paclitaxel Plus Ifosfamide Followed by High-Dose Carboplatin and Etoposide (TI-CE) as First Salvage Treatment in Relapsed or Refractory Germ Cell Tumors | III | 272/420 | N/A | INTERVENTION |
| 10 | A031704 | ALLIANCE | NCTN | Kidney Cancer | Active | PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib with Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE] | III | 122/1046 | N/A | INTERVENTION |
| 11 | A211601 | ALLIANCE | NCORP | Breast Cancer | Active | Evaluation of Mammographic Breast Density Effect of Aspirin: A Companion to Alliance Study A011502 | III | N/A | N/A | OTHER |
| 12 | A211701 | ALLIANCE | NCORP | N/A | Active | A Prospective Study to Establish a New Onset Hyperglycemia and Diabetes (NOD) Cohort | III | N/A | N/A | OTHER |
| 13 | EA6141 | ECOG-ACRIN | NCTN | Skin Cancer | Temporarily Closed to Accrual | Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma | II/III | 250/400 | N/A | INTERVENTION |
| 14 | EA6174 | ECOG-ACRIN | NCTN | Skin Cancer | Active | STAMP: Surgically Treated Adjuvant Merkel cell carcinoma with Pembrolizumab, a Phase III Trial | III | 47/500 | N/A | INTERVENTION |
| 15 | EA8143 | ECOG-ACRIN | NCTN | Kidney Cancer | Active | A Phase 3 RandOmized Study Comparing PERioperative Nivolumab Vs. Observation in Patients with Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC) | III | 450/766 | 506 | SCREENING,INTERVENTION |
| 16 | EA8171 | ECOG-ACRIN | NCTN | Male Reproductive System Cancer | Active | Multiparametric MRI (mpMRI) for Preoperative Staging and Treatment Planning for Newly-Diagnosed Prostate Cancer | II | 156/852 | N/A | INTERVENTION |
| 17 | EA9131 | ECOG-ACRIN | NCORP | Leukemia | Active | A Simplified Patient Care Strategy to Decrease Early Deaths in Acute Promyelocytic Leukemia (APL) | II | 148/200 | N/A | INTERVENTION |
| 18 | EAI142 | ECOG-ACRIN | NCTN | Breast Cancer | Active | [18F] Fluoroestradiol (FES) PET as a Predictive Measure for Endocrine Therapy in Patients with Newly Diagnosed Metastatic Breast Cancer | II | 70/99 | N/A | INTERVENTION |
| 19 | NRG-BR002 | NRG | NCTN | Miscellaneous and Metastatic Cancer | Temporarily Closed to Accrual | A Phase IIR/III Trial of Standard of Care Therapy with or Without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer | II/III | 129/360 | N/A | INTERVENTION |
| 20 | NSABP-B-51 | NRG | NCTN | Breast Cancer | Active | A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy | III | 1480/1636 | N/A | INTERVENTION |
| 21 | RTOG-1112 | NRG | NCTN | Gastrointestinal Cancer | Active | Randomized Phase III Study of Sorafenib Versus Stereotactic Body Radiation Therapy Followed by Sorafenib in Hepatocellular Carcinoma | III | 188/368 | N/A | INTERVENTION |
| 22 | S1512 | SWOG | NCTN | Skin Cancer | Active | A Phase II and Pilot Trial of PD-1 Blockade with MK-3475 (Pembrolizumab) in Patients with Resectable or Unresectable Desmoplastic Melanoma (DM) | II | 36/56 | N/A | INTERVENTION |
| 23 | S1826 | SWOG | NCTN | Lymphoma | Active | A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma | III | 85/987 | N/A | INTERVENTION |
| 24 | 10057 | LAO-NJ066 | ETCTN | Female Reproductive System Cancer;Lymphoma;Skin Cancer | Temporarily Closed to Accrual | A Phase II Study of Talimogene Laherparepvec Followed by Talimogene Laherparepvec + Nivolumab in Refractory T Cell and NK Cell Lymphomas, Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma, and Other Rare Skin Tumors | II | 38/68 | N/A | INTERVENTION |
| 25 | 10061 | LAO-PA015 | ETCTN | Miscellaneous and Metastatic Cancer | Active | A Phase 1 Study of MK-3475 (Pembrolizumab) in Combination with Recombinant Interleukin-12 in Patients with Solid Tumors | I | 14/36 | N/A | INTERVENTION |
| 26 | 10070 | LAO-MD017 | ETCTN | Lung, Mediastinal, and Pleural Cancer;Miscellaneous and Metastatic Cancer | Temporarily Closed to Accrual | Phase 1/2 Study of Navitoclax Plus Vistusertib in Patients with Relapsed Small Cell Lung Cancer (SCLC) and Other Solid Tumors | I/II | 14/24 | N/A | INTERVENTION |
| 27 | 10096 | LAO-CT018 | ETCTN | Male Reproductive System Cancer | Active | A Phase 1/2 Study of Combination Olaparib and Radium-223 in Men with Metastatic Castration-Resistant Prostate Cancer with Bone Metastases (COMRADE) | I/II | 8/18 | N/A | INTERVENTION |
| 28 | 10145 | LAO-NCI | ETCTN | Lymphoma;Miscellaneous and Metastatic Cancer | Active | Phase Ib Combination Study of Copanlisib and Nivolumab in Advanced Solid Tumors and Lymphomas | I | 25/41 | N/A | INTERVENTION |
| 29 | 10146 | LAO-NC010 | ETCTN | Breast Cancer | Temporarily Closed to Accrual | Randomized Phase 2 Clinical Trial of Nab-Paclitaxel + MEDI4736 (Durvalumab) + Neoantigen Vaccine Vs. Nab-Paclitaxel + MEDI4736 (Durvalumab) in Patients with Metastatic Triple Negative Breast Cancer | II | 0/70 | N/A | INTERVENTION |
| 30 | 10166 | LAO-MD017 | ETCTN | Lung, Mediastinal, and Pleural Cancer | Active | A Phase 2 Study of Atezolizumab and Cobimetinib in PD-1/PD-L1 Inhibitor Resistant or Refractory Non-Small Cell Lung Cancer | II | 8/24 | N/A | INTERVENTION |
| 31 | 10170 | LAO-CT018 | ETCTN | Kidney Cancer;Miscellaneous and Metastatic Cancer | Active | A Phase 2 Study of AZD1775 in SETD2-Deficient Advanced Solid Tumor Malignancies | II | 11/60 | N/A | INTERVENTION |
| 32 | 10193 | LAO-MN026 | ETCTN | Lymphoma | Active | Phase 2 Study of Copanlisib in Combination with Nivolumab in Subjects with Relapsed/Refractory Diffuse Large B-Cell Lymphoma and Primary Mediastinal Large B-Cell Lymphoma | II | 1/106 | N/A | INTERVENTION |
| 33 | 10217 | LAO-TX035 | ETCTN | Miscellaneous and Metastatic Cancer | Active | A Phase 1b Biomarker-Driven Combination Trial of Copanlisib, Olaparib, and MEDI4736 (Durvalumab) in Patients with Advanced Solid Tumors | I | 6/102 | N/A | INTERVENTION |
| 34 | 10220 | LAO-TX035 | ETCTN | CNS Cancer (Primary tumor);Lung, Mediastinal, and Pleural Cancer;Miscellaneous and Metastatic Cancer;Soft Tissue Cancer/Sarcoma | Active | A Phase II Basket Trial of Glutaminase Inhibitor (BeGIN) CB-839 HCl in Patients with NF1 Aberrations, NF1 Mutant Malignant Peripheral Nerve Sheath Tumors (MPNST), KEAP1/NRF2 and LKB1 Aberrant Tumors | II | 3/108 | N/A | INTERVENTION |
| 35 | 9948 | LAO-MN026 | ETCTN | Female Reproductive System Cancer | Active | Phase 1 Dose Escalation and Expansion Cohort of Carboplatin and Gemcitabine with or without M6620 (VX-970) in First or Second Recurrence Platinum-Sensitive Epithelial Ovarian, Peritoneal, and Fallopian Tube Cancer | I | 19/24 | N/A | INTERVENTION |
| 36 | A021502 | ALLIANCE | NCTN | Gastrointestinal Cancer | Active | Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair | III | 289/700 | N/A | INTERVENTION |
| 37 | A021703 | ALLIANCE | NCTN | Gastrointestinal Cancer | Active | Randomized Double-Blind Phase III Trial of Vitamin D3 Supplementation in Patients with Previously Untreated Metastatic Colorectal Cancer (SOLARIS) | III | 30/402 | N/A | INTERVENTION |
| 38 | A041501 | ALLIANCE | NCTN | Leukemia | Active | A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) with Newly Diagnosed Precursor B-Cell ALL | III | 103/324 | N/A | INTERVENTION |
| 39 | A051701 | ALLIANCE | NCTN | Lymphoma | Active | Randomized Phase II/III Study of Venetoclax (ABT199) Plus Chemoimmunotherapy for MYC/BCL2 Double-Hit and Double Expressing Lymphomas | II/III | 38/367 | N/A | INTERVENTION |
| 40 | A071401 | ALLIANCE | NCTN | CNS Cancer (Primary tumor) | Temporarily Closed to Accrual | Phase II Trial of SMO/ AKT/ NF2 Inhibitors in Progressive Meningiomas with SMO/ AKT/ NF2 Mutations | II | 40/124 | 322 | SCREENING,INTERVENTION |
| 41 | A151804 | ALLIANCE | NCTN | Miscellaneous and Metastatic Cancer | Active | Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events | Other | 1/240 | N/A | INTERVENTION |
| 42 | A221505 | ALLIANCE | NCORP | Breast Cancer | Active | RT CHARM: Phase III Randomized Trial of Hypofractionated Post Mastectomy Radiation with Breast Reconstruction | III | 487/880 | N/A | INTERVENTION |
| 43 | AREN1721 | COG | NCTN | Kidney Cancer | Active | A Randomized Phase 2 Trial of Axitinib/Nivolumab Combination Therapy vs. Single Agent Nivolumab for the Treatment of TFE/Translocation Renal Cell Carcinoma (tRCC) Across All Age Groups | II | 7/70 | N/A | INTERVENTION |
| 44 | CITN-12 | CITN | MISCELLANEOUS | AIDS-related Malignancy and Condition;Gastrointestinal Cancer;Hematopoietic Neoplasm (excluding Leukemia, Lymphoma and Myeloma);Lung, Mediastinal, and Pleural Cancer;Lymphoma;Miscellaneous and Metastatic Cancer;Skin Cancer | Active | Phase I Study of MK-3475 (Pembrolizumab) in Patients with Human Immunodeficiency Virus (HIV) and Relapsed/Refractory or Disseminated Malignant Neoplasm | I | 39/63 | N/A | INTERVENTION |
| 45 | E4512 | ECOG-ACRIN | NCTN | Lung, Mediastinal, and Pleural Cancer | Active | A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib Versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein | III | 105/168 | N/A | INTERVENTION |
| 46 | EA1131 | ECOG-ACRIN | NCTN | Breast Cancer | Active | A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Capecitabine in Patients with Residual Triple-Negative Breast Cancer following Neoadjuvant Chemotherapy | III | 336/562 | 477 | SCREENING,INTERVENTION |
| 47 | EA2142 | ECOG-ACRIN | NCTN | Endocrine Cancer | Active | Randomized Phase II Study of Platinum and Etoposide Versus Temozolomide and Capecitabine in Patients with Advanced G3 Non-Small Cell Gastroenteropancreatic Neuroendocrine Tumors including Poorly Differentiated Neuroendocrine Carcinomas and Well-Differentiated Neuroendocrine Neoplasms | II | 50/80 | N/A | INTERVENTION |
| 48 | EA5162 | ECOG-ACRIN | NCTN | Lung, Mediastinal, and Pleural Cancer | Temporarily Closed to Accrual | Phase II Study of AZD9291 (Osimertinib) in Advanced NSCLC Patients with Exon 20 Insertion Mutations in EGFR | II | 21/20 | N/A | INTERVENTION |
| 49 | EAF151 | ECOG-ACRIN | NCTN | CNS Cancer (Primary tumor) | Active | Change in Relative Cerebral Blood Volume as a Biomarker for Early Response to Bevacizumab in Patients with Recurrent Glioblastoma | II | 65/165 | N/A | INTERVENTION |
| 50 | EAQ162CD | ECOG-ACRIN | CCDR | Gastrointestinal Cancer | Active | Longitudinal Assessment of Financial Burden in Patients with Colon or Rectal Cancer Treated with Curative Intent | Other | N/A | N/A | OTHER |